Clinical Trials Logo

Lymphomas Non-Hodgkin's B-Cell clinical trials

View clinical trials related to Lymphomas Non-Hodgkin's B-Cell.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03029338 Completed - Relapse Clinical Trials

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Start date: June 8, 2017
Phase: Phase 1
Study type: Interventional

In this single-center, open-label, no control, prospective clinical trial, a total of 10 relapsed or refractory CD19 positive B-cell Non-Hodgkin Lymphoma (NHL) patients will be enrolled.CD19 CAR T cells(total dose of 2×10^6/kg-1×10^7/kg) will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2. The purpose of current study is to determine the clinical efficacy and safety of CD19 CAR T cells in patients with relapsed or refractory CD19 positive B-cell lymphoma.